The aim of treatment for ApHCM is mainly to control symptoms and prevent complications, which are done by means of medications such as beta-blockers or calcium-channel blockers to control the heart rate, and also ACEI
to reduce the left ventricular afterload.
Objective: To ascertain the effectiveness of immunosuppressants along with ACEI
and /or ARBS in proteinuria in patients with solitary kidney post nephrectomy.
Hicks, Ph.D., from Jewish General Hospital in Montreal, and colleagues conducted a population-based cohort study involving 992,061 patients newly treated with antihypertensive drugs to examine whether use of ACEIs
versus angiotensin receptor blockers was correlated with the risk for lung cancer.
Earlier studies have hinted that ACEIs
might increase people's cancer risk, but findings have not been conclusive; most existing studies only had access to relatively small sample sizes or for short periods of time.
They also replace angiotensin receptor blockers (ARBs), which are an acceptable substitute for patients who cannot tolerate ACEIs
Results: Compared with the normal renal function group and the slight decrease group, ACEIs
and [beta]-blockers were less used in the moderate and severe decrease group, but diuretics and spironolactone were more used (P<0.05).
There are numerous classes of medications used to treat high blood pressure; they include diuretics, angiotensin-converting enzyme inhibitors (ACEIs
), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), beta-receptor blockers, and alpha-receptor blockers.
These include angiotensin-converting enzyme inhibitors (ACEis
) and, when ACEis
are contraindicated, angiotensin receptor blockers (ARBs) and loop diuretics.
In the context of specific therapies for the treatment or delay of CKD progression, do we know if there are sex differences in therapeutic responses to angiotensin-converting enzyme inhibitors (ACEIs
) and angiotensin receptor blockers (ARBs)?
Surprisingly, the use of ACEIs
was not a protective factor.
** Aminoglycoside, furosemide, amphotericin B, colistin, ACEIs
, ARBs, NSAID, tacrolimus, acyclovir, and cyclosporine.
ACE inhibitors (ACEIs
) and beta-blockers have been associated with decreased mortality in clinical trials.